Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barbara Henley

Urogynecology and Reconstructive Pelvic Surgery Augusta, GA Medical Doctor

NPI 1912063728 CMS profile 86805

1120 15Th St, Medical Office Building, Augusta, GA 30912

Open in the dashboard

General payments

$36,605

440 records reported · program years 2019–2025

Research payments

$650

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,600 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Barbara Henley of Augusta, GA is reported in the CMS Open Payments database as having received $36,605 across 440 general payments and $650 in research payments paid to them. Separately, studies naming them as principal investigator received $7,600 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,350 22
2024 General $4,822 27
2023 General $8,492 59
2023 Research $650 1
2022 General $6,478 91
2021 General $5,426 75
2020 General $4,924 87
2019 General $5,114 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Henley
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Barbara Henley were reported at $1,350. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Barbara Henley Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $5,114 $358 $132–$1,270 $163
2020 $4,924 $198 $86–$642 $114
2021 $5,426 $361 $118–$1,182 $132
2022 $6,478 $410 $128–$1,175 $149
2023 $8,492 $434 $152–$1,344 $160
2024 $4,822 $494 $193–$1,331 $164
2025 $1,350 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $14,576 49 payments
  2. Allergan Inc. $11,187 65 payments
  3. Medtronic, Inc. $4,289 94 payments
  4. Boston Scientific Corporation $1,444 19 payments
  5. Axonics Modulation Technologies, Inc. $1,370 44 payments
  6. Medtronic USA, Inc. $1,254 49 payments
  7. Astellas Pharma US Inc $915 51 payments
  8. Coloplast Corp $529 26 payments
  9. Pfizer Inc. $306 18 payments
  10. Urovant Sciences Inc $219 7 payments
  11. Other $517 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,463 26 payments
  2. Food and Beverage $11,498 401 payments
  3. Travel and Lodging $1,136 9 payments
  4. Consulting Fee $325 1 payment
  5. Education $184 3 payments
Products named General payments · program years 2019–2025
  1. BOTOX Urology $15,626 21 payments
  2. INTERSTIM Sacral Nerve Stimulation $3,913 87 payments
  3. BOTOX Urology $3,525 6 payments
  4. BOTOX Urology $3,200 7 payments
  5. BOTOX Botox Therapeutic $2,220 15 payments
  6. INTERSTIM Sacral Nerve Stimulation $1,254 49 payments
  7. Solyx SIS System $1,152 11 payments
  8. BOTOX Hyperhydrosis $1,011 56 payments
  9. Axonics $740 19 payments
  10. MYRBETRIQ $642 43 payments
  11. Other $3,595 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $650 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

283

Median for Obstetrics & Gynecology: 65

Drug cost

$40,028

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

30.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 41 $25,833
Gemtesa Vibegron Brand 13 $9,050
Estradiol Generic 77 $4,494
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 18 $228
Ibuprofen Generic 27 $226
Ondansetron Hcl Generic 25 $56
Tamsulosin Hcl Generic 23 $40
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $39
Gabapentin Generic 23 $35
Tramadol Hcl Generic 22 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$55,678

Medicare's payments for the services billed

Medicare patients

123

Average age 74

Services billed

783

123 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 59%
High blood pressure 55%
Diabetes 24%
Ischemic heart disease 24%
Osteoporosis 21%
Depression 17%
Chronic kidney disease 14%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $4,002
$4,002 — —
Veozah
  • Astellas Pharma US Inc $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record